January 22, 2015
The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) Second Committee on Drugs recommended approval for Eisai’s lenvatinib mesylate for unresectable thyroid cancer at a meeting on January 21. Lenvatinib is an oral drug that selectively inhibits a number of enzymes...read more